Catherine A. Cosgrove

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Characterization of <i>Salmonella enterica</i> Derivatives Harboring Defined <i>aroC</i> and <i>Salmonella</i> Pathogenicity Island 2 Type III Secretion System ( <i>ssaV</i> ) Mutations by Immunization of Healthy Volunteers

Zoë Hindle, Steven N. Chatfield, Jo Phillimore et al. · Infection and Immunity · 2002 · 202 citations · Full text

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Katrina M. Pollock, Hannah M. Cheeseman, Alexander J. Szubert et al. · EClinicalMedicine · 2022 · 149 citations · Full text

Clinical Application of Whole-Genome Sequencing To Inform Treatment for Multidrug-Resistant Tuberculosis Cases

Adam A. Witney, Katherine A. Gould, Amber Arnold et al. · Journal of Clinical Microbiology · 2015 · 106 citations · Full text

Tuberculosis Prevention, Antibiotic Resistance, High Throughput Sequencing +23